Article
Medicine, General & Internal
Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Carolyn Bramante, Upinder Singh, Rowena J. Dolor, Juan Ruiz-Unger, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez
Summary: This study aimed to evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily for 10 days) compared with placebo for the treatment of mild to moderate COVID-19. The results showed that treatment with fluvoxamine did not improve the time to sustained recovery compared with placebo. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, Alex J. Slandzicki, Stephen C. Lim, Jonathan Cohen, David Kavtaradze, Arch P. Amon, Ahab Gabriel, Nina Gentile, G. Michael Felker, Dushyantha Jayaweera, Matthew W. McCarthy, Mark Sulkowski, Russell L. Rothman, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George J. Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez
Summary: The study evaluated the effectiveness of ivermectin at a maximum targeted dose of 600 μg/kg daily for 6 days in the treatment of early mild to moderate COVID-19. The results showed that compared to placebo, ivermectin treatment did not improve the time to sustained recovery, suggesting no benefits of ivermectin for patients with mild to moderate COVID-19.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Tatsuhiko Wada, Makoto Hibino, Hiromi Aono, Shunsuke Kyoda, Yosuke Iwadate, Eri Shishido, Keisuke Ikeda, Nana Kinoshita, Yasuki Matsuda, Sakiko Otani, Ryo Kameda, Kenta Matoba, Miwa Nonaka, Mika Maeda, Yuji Kumagai, Junya Ako, Masayoshi Shichiri, Katsuhiko Naoki, Masato Katagiri, Masashi Takaso, Masatsugu Iwamura, Kazuhiko Katayama, Takeshi Miyatsuka, Yasushi Orihashi, Kunihiro Yamaoka
Summary: This study aimed to investigate whether ivermectin inhibits SARS-CoV-2 proliferation in patients with mild-to-moderate COVID-19. The results showed that a single oral dose of ivermectin did not significantly affect the time to a negative RT-PCR test for COVID-19.
FRONTIERS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Mohammad Sadegh Rezai, Fatemeh Ahangarkani, Andrew Hill, Leah Ellis, Manya Mirchandani, Alireza Davoudi, Gohar Eslami, Fatemeh Roozbeh, Farhang Babamahmoodi, Nima Rouhani, Ahmad Alikhani, Narges Najafi, Roya Ghasemian, Hossein Mehravaran, Azin Hajialibeig, Mohammad Reza Navaeifar, Leila Shahbaznejad, Golnar Rahimzadeh, Majid Saeedi, Reza Alizadeh-Navai, Mahmood Moosazadeh, Shahab Saeedi, Seyedeh-Kiana Razavi-Amoli, Shaghayegh Rezai, Fereshteh Rostami-Maskopaee, Fatemeh Hosseinzadeh, Faezeh Sadat Movahedi, John S. Markowitz, Reza Valadan
Summary: The study results indicate that ivermectin as a treatment for COVID-19 did not have a significant effect on improving clinical symptoms or reducing hospital admissions and mortality rates.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, Research & Experimental
Anan Manomaipiboon, Kittisak Pholtawornkulchai, Sujaree Poopipatpab, Swangjit Suraamornkul, Jakravoot Maneerit, Wiroj Ruksakul, Uraporn Phumisantiphong, Thananda Trakarnvanich
Summary: This study found that there was no difference in reducing PCR-positive cases after treatment with ivermectin compared to standard care among patients with mild to moderate COVID-19 symptoms. However, early symptomatic improvement was observed without any side effects.
Article
Medicine, General & Internal
Steven Chee Loon Lim, Chee Peng Hor, Kim Heng Tay, Anilawati Mat Jelani, Wen Hao Tan, Hong Bee Ker, Ting Soo Chow, Masliza Zaid, Wee Kooi Cheah, Han Hua Lim, Khairil Erwan Khalid, Joo Thye Cheng, Hazfadzila Mohd Unit, Noralfazita An, Azraai Bahari Nasruddin, Lee Lee Low, Song Weng Ryan Khoo, Jia Hui Loh, Nor Zaila Zaidan, Suhaila Ab Wahab, Li Herng Song, Hui Moon Koh, Teck Long King, Nai Ming Lai, Suresh Kumar Chidambaram, Kalaiarasu M. Peariasamy
Summary: This study aimed to evaluate the efficacy of ivermectin in high-risk patients with COVID-19. The results showed that early treatment with ivermectin did not prevent disease progression and did not support its use for COVID-19 patients.
JAMA INTERNAL MEDICINE
(2022)
Article
Microbiology
Claudio Ucciferri, Alessandro Di Gasbarro, Paola Borrelli, Marta Di Nicola, Jacopo Vecchiet, Katia Falasca
Summary: This study found that the use of pidotimod in patients with mild-moderate COVID-19 can reduce the need for hospitalization and shorten the duration of illness. Patients in the pidotimod group had higher SpO2 in the walking test and a lower need for steroid rescue therapy.
Article
Chemistry, Multidisciplinary
Ozlem Altay, Muhammad Arif, Xiangyu Li, Hong Yang, Mehtap Aydin, Gizem Alkurt, Woonghee Kim, Dogukan Akyol, Cheng Zhang, Gizem Dinler-Doganay, Hasan Turkez, Saeed Shoaie, Jens Nielsen, Jan Boren, Oktay Olmuscelik, Levent Doganay, Mathias Uhlen, Adil Mardinoglu
Summary: The administration of a mixture of combined metabolic activators (CMAs) to COVID-19 patients can restore metabolic function, accelerate recovery, and improve plasma levels of proteins and metabolites, revealing the potential mechanism of treatment.
Article
Clinical Neurology
Konrad Rejdak, Piotr Fiedor, Robert Bonek, Jacek Lukasiak, Waldemar Chelstowski, Slawomir Kiciak, Piotr Dabrowski, Agnieszka Gala-Bladzinska, Mateusz Dec, Ewa Papuc, Adriana Zasybska, Marcin Kaczor, Pawel Grieb, COV PREVENT Study Group
Summary: This study aimed to evaluate the effectiveness of amantadine in preventing the progression of COVID-19 and its neurological sequelae. The results showed that the amantadine group had better outcomes in terms of disease progression, improvement in taste and smell, but no improvement in fatigue compared to the placebo group.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Bruno Dubois, Jesus Lopez-Arrieta, Stanley Lipschitz, Doskas Triantafyllos, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. D. Mansfield, Olivier Hermine, Magda Tsolaki
Summary: The study found that the tyrosine kinase inhibitor masitinib, when administered orally, can be beneficial as an adjunct treatment for mild-to-moderate Alzheimer's disease. It showed significant improvement in cognitive and functional abilities, with side effects consistent with known information. Further research is ongoing to validate these results.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Article
Immunology
Seyed Mehran Marashian, Mohammadreza Hashemian, Mihan Pourabdollah, Mansour Nasseri, Saeed Mahmoudian, Florian Reinhart, Alireza Eslaminejad
Summary: This study suggests that photobiomodulation (PBM) therapy may be effective in inhibiting the release of pro-inflammatory cytokines in COVID-19 patients, reducing organ damage and preventing severe disease progression.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Medicinal
Maedeh Chegini, Amir Sadeghi, Farid Zaeri, Majid Zamani, Azita Hekmatdoost
Summary: This study investigated the effectiveness of nano-curcumin as an anti-inflammatory agent in patients with mild and moderate acute pancreatitis (AP). It was a double-blind, parallel-arm randomized controlled trial conducted in Tehran, Iran. The results showed that nano-curcumin supplementation reduced hospital length of stay, decreased the need for analgesics, and improved overall appetite in patients with AP. No adverse effects or mortality were reported. Further larger-scale multi-center trials are needed to confirm these findings.
PHYTOTHERAPY RESEARCH
(2023)
Article
Public, Environmental & Occupational Health
Alireza Malektojari, Sara Ghazizadeh, Mohammad Ersi, Elham Brahimi, Soheil Hassanipour, Mohammad Fathalipour, Mehdi Hassaniazad
Summary: The objective of this study was to evaluate the effectiveness and safety of ivermectin in patients with mild and moderate COVID-19. The results showed no significant difference between the ivermectin group and the control group in terms of hospital stay, ICU admission, ICU stay, in-hospital mortality, adverse drug reactions, and changes in laboratory data. Therefore, the administration of a single dose of ivermectin in a five-day course did not significantly improve clinical outcomes or mortality in hospitalized COVID-19 patients.
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE
(2023)
Article
Immunology
Francisco Fuentes-Villalobos, Jose L. Garrido, Matias A. Medina, Nicole Zambrano, Natalia Ross, Felipe Bravo, Aracelly Gaete-Argel, Aaron Oyarzun-Arrau, Fatima Amanat, Ricardo Soto-Rifo, Fernando Valiente-Echeverria, Renato Ocampo, Christian Esveile, Leonila Ferreira, Johanna Cabrera, Vivianne Torres, Maria L. Rioseco, Raul Riquelme, Sebastian Barria, Raymond Alvarez, Yazmin Pinos, Florian Krammer, Mario Calvo, Maria I. Barria
Summary: The study reveals that antibody-mediated natural killer cell activity is an important function of the humoral response against the SARS-CoV-2 spike protein, in addition to neutralization.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Infectious Diseases
Anant Mohan, Pawan Tiwari, Tejas Menon Suri, Saurabh Mittal, Ankit Patel, Avinash Jain, Thirumurthy Velpandian, Ujjalkumar Subhash Das, Tarun Krishna Boppana, Ravindra Mohan Pandey, Sushil Suresh Shelke, Angel Rajan Singh, Sushma Bhatnagar, Shet Masih, Shelly Mahajan, Tanima Dwivedi, Biswajeet Sahoo, Anuja Pandit, Shweta Bhopale, Saurabh Vig, Ritu Gupta, Karan Madan, Vijay Hadda, Nishkarsh Gupta, Rakesh Garg, Ved Prakash Meena, Randeep Guleria
Summary: In this study on hospitalized patients with mild-to-moderate COVID-19, a single oral dose of Ivermectin did not significantly increase RT-PCR negativity or decline in viral load at day 5 compared to placebo.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2021)
Article
Immunology
David R. Boulware, Thomas A. Murray, Jennifer L. Proper, Christopher J. Tignanelli, John B. Buse, David M. Liebovitz, Jacinda M. Nicklas, Kenneth Cohen, Michael A. Puskarich, Hrishikesh K. Belani, Lianne K. Siegel, Nichole R. Klatt, David J. Odde, Amy B. Karger, Nicholas E. Ingraham, Katrina M. Hartman, Via Rao, Aubrey A. Hagen, Barkha Patel, Sarah L. Fenno, Nandini Avula, Neha Reddy, Spencer M. Erickson, Sarah Lindberg, Regina Fricton, Samuel Lee, Adnin Zaman, Hanna G. Saveraid, Walker J. Tordsen, Matthew F. Pullen, Nancy E. Sherwood, Jared D. Huling, Carolyn T. Bramante
Summary: SARS-CoV-2 vaccine-boosted participants experienced the least severe symptoms during COVID-19, and their symptoms improved the fastest over time. Vaccination against SARS-CoV-2 was found to be associated with reduced symptom severity in a sample of low to moderate risk adults enrolled in an outpatient COVID-19 treatment trial. Booster shots further reduced symptom severity.
CLINICAL INFECTIOUS DISEASES
(2023)
Letter
Critical Care Medicine
Yike Li, Kelsey E. Richard, Alan R. Schwartz, David Zealear, Christopher J. Lindsell, Holly A. Budnick, David T. Kent
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Immunology
Mark W. Tenforde, Manish M. Patel, Nathaniel M. Lewis, Katherine Adams, Manjusha Gaglani, Jay S. Steingrub, Nathan Shapiro, Abhijit Duggal, Matthew E. Prekker, Ithan D. Peltan, David N. Hager, Michelle N. Gong, Matthew C. Exline, Adit A. Ginde, Nicholas M. Mohr, Christopher Mallow, Emily T. Martin, H. Keipp Talbot, Kevin W. Gibbs, Jennie H. Kwon, James D. Chappell, Natasha Halasa, Adam S. Lauring, Christopher J. Lindsell, Sydney A. Swan, Kimberly W. Hart, Kelsey N. Womack, Adrienne Baughman, Carlos G. Grijalva, Wesley H. Self
Summary: During the 2021-2022 US influenza season, circulating A(H3N2) viruses were antigenically different from the vaccine. The vaccine effectiveness against hospitalized illness was 26% (95% CI: -14-52%) for adults 18-64 years old and -3% (95% CI: -54-31%) for adults ≥ 65 years old. Our study showed that the influenza vaccine had some effectiveness in preventing hospitalization among immunocompetent adults aged 18-64, but provided no significant protection for adults ≥ 65.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Carolyn Bramante, Upinder Singh, Rowena J. Dolor, Juan Ruiz-Unger, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez
Summary: This study aimed to evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily for 10 days) compared with placebo for the treatment of mild to moderate COVID-19. The results showed that treatment with fluvoxamine did not improve the time to sustained recovery compared with placebo. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Oncology
Andreana N. Holowatyj, Wanqing Wen, Timothy Gibbs, Hannah M. Seagle, Samantha R. Keller, Digna R. Velez Edwards, Mary K. Washington, Cathy Eng, Jose Perea, Wei Zheng, Xingyi Guo
Summary: This study investigated somatic mutation patterns in colorectal cancer patients of different races/ethnicities and sexes, finding that non-Hispanic Black and Asian/Pacific Islander patients with early-onset nonhypermutated colorectal cancer had higher tumor mutation rates compared to non-Hispanic white patients. Significant differences were observed in the mutation frequencies of several genes between racial/ethnic groups in early-onset nonhypermutated colorectal cancers. Furthermore, heterogeneity was observed in the effects of certain genes between early-onset and late-onset nonhypermutated colorectal cancer, as well as between males and females. These findings provide important insights into the genomic patterns and disparities of early-onset colorectal cancer based on race/ethnicity and sex.
Article
Medicine, General & Internal
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Vitoria Helena de Souza Campos, Thiago Santiago Ferreira, Castilho Vitor Quirino dos Santos, Ana Maria Ribeiro Nogueira, Ana Paula Figueiredo Guimaraes Almeida, Leonardo Cancado Monteiro Savassi, Adhemar Dias de Figueiredo Neto, Carina Bitaraes, Aline Cruz Milagres, Eduardo Diniz Callegari, Maria Izabel Campos Simplicio, Luciene Barra Ribeiro, Rosemary Oliveira, Ofir A. Harari, Lindsay A. Wilson, Jamie Forrest, Hinda Ruton, Sheila Sprague, Paula McKay, Christina M. Guo, Gordon H. Guyatt, Craig R. Rayner, David R. Boulware, Nicole Ezer, Todd C. Lee, Emily Gibson McDonald, Mona Bafadhel, Christopher Butler, Josue Rodrigues Silva, Mark J. Dybul, Edward Mills
Summary: This study aimed to determine whether the combination of fluvoxamine and inhaled budesonide would increase treatment effects in a highly vaccinated population. The results showed that the proportion of patients observed in an emergency setting or hospitalized due to COVID-19 was lower in the treatment group than the placebo group, suggesting that the combination treatment can reduce the risk of disease progression.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Immunology
Elizabeth Nalintya, Preethiya Sekar, Paul Kavuma, Joanita Kigozi, Martin Ssuna, Paul Kirumira, Rose Naluyima, Teopista Namuli, Fred Turya Musa, Caleb P. Skipper, Kathy Huppler Hullsiek, Jayne Ellis, David R. Boulware, David B. Meya, Radha Rajasingham
Summary: Based on data from Ugandan HIV clinics between July 2019 and January 2022, there has been a 40% reduction in the number of individuals seeking care for HIV after August 2021 compared to pre-pandemic levels. Additionally, a greater proportion of people are presenting with advanced HIV disease (20% vs 16% in the pre-COVID-19 period).
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Alessandro C. Pasqualotto, Daiane Dalla Lana, Cassia S. M. Godoy, Terezinha do Menino Jesus Silva Leitao, Monica B. Bay, Lisandra Serra Damasceno, Renata B. A. Soares, Roger Kist, Larissa R. Silva, Denusa Wiltgen, Marineide Melo, Taiguara F. Guimaraes, Marilia R. Guimaraes, Hareton T. Vechi, Jaco R. L. de Mesquita, Gloria Regina de G. Monteiro, Antoine Adenis, Nathan C. Bahr, Andrej Spec, David R. Boulware, Dennis Israelski, Tom Chiller, Diego R. Falci
Summary: This is the first trial to show that AIDS patients with disseminated histoplasmosis can be safely and effectively treated with a single high dose of liposomal amphotericin B (10 mg/kg).
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Alexander M. Kaizer, Nathan I. Shapiro, Jessica Wild, Samuel M. Brown, B. Jessica Cwik, Kimberly W. Hart, Alan E. Jones, Michael S. Pulia, Wesley H. Self, Clay Smith, Stephanie A. Smith, Patrick C. Ng, B. Taylor Thompson, Todd W. Rice, Christopher J. Lindsell, Adit A. Ginde
Summary: This study aimed to evaluate the efficacy and safety of lopinavir/ritonavir (LPV/r) for early treatment of non-hospitalized individuals with COVID-19. The results showed that LPV/r did not significantly improve symptom resolution or reduce hospitalization in non-hospitalized participants.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, Alex J. Slandzicki, Stephen C. Lim, Jonathan Cohen, David Kavtaradze, Arch P. Amon, Ahab Gabriel, Nina Gentile, G. Michael Felker, Dushyantha Jayaweera, Matthew W. McCarthy, Mark Sulkowski, Russell L. Rothman, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George J. Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez
Summary: The study evaluated the effectiveness of ivermectin at a maximum targeted dose of 600 μg/kg daily for 6 days in the treatment of early mild to moderate COVID-19. The results showed that compared to placebo, ivermectin treatment did not improve the time to sustained recovery, suggesting no benefits of ivermectin for patients with mild to moderate COVID-19.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Oncology
Hannah M. Seagle, Samantha R. Keller, Sean V. Tavtigian, Carolyn Horton, Andreana N. Holowatyj
Summary: Germline genetic predisposition in early-onset colorectal cancer (EOCRC) varies across racial/ethnic groups. Current multigene panel tests may not accurately assess the risk of EOCRC in diverse populations.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Infectious Diseases
Tyler J. Stone, Abdullah Kilic, John C. Williamson, Elizabeth L. Palavecino
Summary: The in vitro activity of omadacycline and comparator antibiotics against clinical ESBL-producing and non-ESBL-producing E. coli and K. pneumoniae urinary isolates was evaluated. Results showed that 54.9% of all ESBL-producing isolates and 74.5% of ESBL-producing E. coli isolates were susceptible to omadacycline. Overall, omadacycline and nitrofurantoin were the most active agents for treating UTI caused by ESBL-producing E. coli.
Article
Medicine, General & Internal
Nalini Ambrose, Alpesh Amin, Brian Anderson, Julio Barrera-Oro, Monica Bertagnolli, Francis Campion, Daniel Chow, Risa Danan, Lauren D'Arinzo, Ashley Drews, Karl Erlandson, Kristin Fitzgerald, Melissa Garcia, Fraser W. Gaspar, Carlene Gong, George Hanna, Stephen Jones, Bert Lopansri, James Musser, John O'Horo, Steven Piantadosi, Bobbi Pritt, Raymund R. Razonable, Seth Roberts, Suzanne Sandmeyer, David Stein, Farhaan Vahidy, Brandon Webb, Jennifer Yttri
Summary: This study aimed to assess the safety of nMAb treatment for COVID-19 and its association with adverse outcomes. The study found that nMAb treatment was associated with reductions in ED visits, hospitalization, and death within 30 days, but not with reduced risk of hospitalization during the Omicron BA.1 epoch. Rating: 8/10.
Editorial Material
Health Care Sciences & Services
Boghuma K. Titanji, David R. Boulware, Rachel A. Bender Ignacio
Summary: This Viewpoint identifies areas that need improvement in the implementation of future epidemic clinical trials, particularly in research involving nonhospitalized individuals.